Aspen’s bitter pill: Is it worth a second opinion?
The loss of a key mRNA manufacturing deal and FDA warnings have hit Aspen hard — but its global reach and sterile capacity could yet deliver a turnaround
08 May 2025 - 05:00
Aspen Pharmacare has taken its medicine this past week, its share price turning a worrying shade of pale after a nasty business update infected investor sentiment.
Still, it’s worth giving the group a full physical to assess how it might overcome its current ailments...
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.